Journal Banner

Intralesional steroid for Infantile Parotid Hemangiomas: An understanding with a case report

Hemangiomas are the most common parotid gland tumours in children. These lesions com-monly go unnoticed in the newborn period but become conspicuous in the initial months of life. They increase in size during the first year of life and typically regress during the next decade. The presentation of heman-gioma is variable in relation with their size, extent and morphology (1). These may be part of a V3 mandibular segment hemagioma associated invariably with cutaneous involve-ment and occasionally with airway involve-ment, or they may present as isolated focal hemangioma (2). These lesions display fe-male predilection. There is an increased fre-quency of hemangiomas in premature infants and are uncommonly seen in dark skinned infants (1). In the first year of life, hemangiomas account for approximately 50% of parotid tumours (3). Because these lesions have an affinity for ecto-derm, the parotid gland and the minor salivary glands of the lower lip mucosa are the only sali-vary gland affected (4). Diagnosis can be estab-lished by various diagnostic techniques like ul-transonography, computed tomography or MRI. Owing to the benign nature of these hemangio-mas, many authors favour conservative, non-operative treatment, including corticosteroids (systemic or intra-lesional), interferon, pro-pranolol and various sclerosants. We here present a child with a parotid heman-gioma involving both lobes of parotid who showed substantial regression following intrale-sional dexamethasone along with an insight into review of literature.

Author(s): Anju Chauhan, Vikram Wadhwa, Samuel Rajan , P.K. Rathore